 enhanc hepat drug clearanc patient cystic fibrosi hepat drug metabol patient cystic fibrosi CF pharmacokinet model pharmacolog substrat antipyrin marker hepat oxid metabol marker hepat glucuronosyltransferas activ green icg marker hepat blood flow biliari secret patient CF year age children adolesc cancer year age surgeri radiat studi subject singl intraven dose combin model substrat mg/kg lorazepam mg/kg antipyrin mg/kg icg minut blood sampl postinfus period patient CF plasma clearanc lorazepam vs icg vs antipyrin vs comparison control subject appar steady-st volum distribut lorazepam icg antipyrin patient CF control subject clearanc model standard biochem marker hepat function signific relationship clearanc steady-st volum distribut compound nation health prognost score patient CF data demonstr plasma clearanc lorazepam icg patient CF hepat glucuronosyltransferas activ biliari secretori capac diseas